Welcome to our dedicated page for Scinai Immunotherapeutics Ltd. news (Ticker: $SCNI), a resource for investors and traders seeking the latest updates and insights on Scinai Immunotherapeutics Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scinai Immunotherapeutics Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scinai Immunotherapeutics Ltd.'s position in the market.
Scinai Immunotherapeutics announces receipt of a Nasdaq Staff determination letter regarding noncompliance with minimum shareholders' equity requirements. A hearing with the Nasdaq Hearings Panel is scheduled for June 18, 2024, where the company will present a plan to regain compliance. The plan may include converting part of a loan from the European Investment Bank into equity. The company has also received a notification regarding noncompliance with the minimum $1.00 bid price requirement. To address this, a ratio change of the ADSs to non-traded ordinary shares was implemented, equivalent to a reverse split of 1 for 10. Despite these issues, SCNI's ADSs will continue trading under the symbol 'SCNI' pending the outcome of the hearing.
Scinai Immunotherapeutics has released its financial results for FY 2023, reporting a net loss of $6.5 million, an increase from $5.8 million in 2022. The company raised $1.69 million in January 2024 through warrant exercises and secured a grant from the Israel Innovation Authority covering 66% of a CDMO project. Scinai's CDMO unit reported $500K in work orders for early 2024, projecting $1.25 million in revenue for the year. In its pipeline, Scinai highlighted positive preclinical results for its anti-IL-17 NanoAbs for psoriasis and ongoing strategic partnerships for COVID-19 treatments. The company also saw a decrease in R&D and administrative expenses but reported lower financial income and reduced cash reserves of $4.9 million as of December 31, 2023.
Scinai Immunotherapeutics (Nasdaq: SCNI) has received a delisting notification from Nasdaq due to non-compliance with the minimum $1.00 bid price requirement. The company is appealing the determination and has approved a ratio change of its ADSs to non-traded ordinary shares, equivalent to a reverse split, to regain compliance. No action is required by the ADS holders for the ratio change, which is expected to be effective on May 21, 2024.